Patents Assigned to Bioscience, Inc.
  • Peptide constructs and assay systems
    Patent number: 9958454
    Abstract: The present invention provides methods for constructing peptide construct sets and methods of use of these peptide construct sets in assay systems for peptide analysis, and in particular for use in high throughput peptide analysis. The methods allow for analysis of large sets of peptide constructs in a cost-effective manner, employing molecular biological techniques that are both robust and easily parallelized. Thus, the methods allow for the construction of peptide construct sets encompassing, e.g., the human proteome.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 1, 2018
    Assignee: Prognosys Biosciences, Inc.
    Inventors: Igor A. Kozlov, Mark S. Chee, Petr Capek, David A. Routenberg
  • Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
    Patent number: 9956205
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: May 1, 2018
    Assignee: Ardea Biosciences, Inc.
    Inventors: Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
  • Cells comprising engineered nucleic-acid targeting nucleic acids
    Patent number: 9957490
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 1, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • VIRION-DERIVED NANOSPHERES FOR SELECTIVE DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS TO CANCER CELLS
    Publication number: 20180110883
    Abstract: The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and/or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects.
    Type: Application
    Filed: November 28, 2017
    Publication date: April 26, 2018
    Applicant: Aura Biosciences, Inc.
    Inventors: Elisabet de los Pinos, Rhonda C. Kines
  • Compositions and methods for inhibiting beta-lactamase
    Patent number: 9951072
    Abstract: Substituted dihydroisoxazole derivatives useful as inhibitors of ?-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 24, 2018
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Hye Kyung Chang, Sung Yoon Baek, Min Jung Kim, Kyu Man Oh, Jeung Soon Choi, Soo Bong Ha, Sung Min Kim, Chul-woong Chung, Dae Hyuck Kang, Hyun Jin Kwon, Young Lag Cho, Yong Zu Kim
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9950010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9950011
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9951073
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 24, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventor: Jayhong A. Chong
  • Methods of using pegylated interleukin-10 for treating cancer
    Patent number: 9943568
    Abstract: Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: April 17, 2018
    Assignee: ARMO BioSciences, Inc.
    Inventor: Martin Oft
  • Etanercept formulations stabilized with combinations of sugars and polyols
    Patent number: 9943601
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: April 17, 2018
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • HEPATITIS B VIRAL ASSEMBLY EFFECTORS
    Publication number: 20180099952
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
  • Methods and compositions for analyzing proteins
    Patent number: 9939447
    Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 10, 2018
    Assignee: Monogram Biosciences, Inc.
    Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
  • Heterocyclic inhibitors of glutaminase
    Patent number: 9938267
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 10, 2018
    Assignee: Calithera Biosciences, Inc.
    Inventors: Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
  • Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
    Patent number: 9938558
    Abstract: Methods, apparatuses, and systems for screening, analyzing and selecting microorganisms from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and synthesizing microbial ensembles based thereon are disclosed. Methods for identifying and determining the absolute cell count of microorganism types and strains, along with identifying the network relationships between active microorganisms and environmental parameters, are also disclosed.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: April 10, 2018
    Assignee: Ascus Biosciences, Inc.
    Inventor: Mallory Embree
  • METHODS AND COMPOSITIONS FOR TREATING PAIN
    Publication number: 20180093986
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 5, 2018
    Applicants: Hydra Biosciences, Inc., Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20180092374
    Abstract: This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk. The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 5, 2018
    Applicant: Prolacta Bioscience, Inc.
    Inventors: Joseph FOURNELL, Scott EAKER, Scott ELSTER, David J. RECHTMAN
  • AUTOMATED CELL CULTURE INCUBATOR
    Publication number: 20180087020
    Abstract: Aspects relate to an automated cell culture incubator and to methods for using such an incubator. In one aspect, the cell culture incubator includes an incubator cabinet having a transfer chamber and an internal chamber that are arranged to form an airlock configuration. In some embodiments, objects placed into the incubator cabinet are sterilized using ozone produced by an ozone generator. The incubator may include one or more transfer devices that move objects between the transfer chamber and the internal chamber.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 29, 2018
    Applicant: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • CELL CULTURE INCUBATORS WITH INTEGRATED CELL MANIPULATION SYSTEMS
    Publication number: 20180087021
    Abstract: Aspects of the invention relate to automated cell culture incubators. In some embodiments, automated cell culture incubators comprise an integrated manipulation having one or more cell scrapers.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 29, 2018
    Applicant: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • CELL-FREE PRODUCTION OF RIBONUCLEIC ACID
    Publication number: 20180087045
    Abstract: Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid.
    Type: Application
    Filed: March 30, 2016
    Publication date: March 29, 2018
    Applicant: GreenLight Biosciences, Inc.
    Inventors: William Jeremy Blake, Drew S. Cunningham, Daniel MacEachran
  • Furanone derivative
    Patent number: RE46815
    Abstract: To provide a novel furanone derivative, and a medicine including the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: May 1, 2018
    Assignee: Carna Biosciences, Inc.
    Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka